Patents Expire for Liptor and Zyprexa, Oracea Small Fry

Written by on January 19, 2012 in Galderma, patents with 0 Comments

While us in the rosacea world might consider products that are expensive while they are covered by exclusive patents, we are small fry in the drug market at large.

Patents are due to shortly expire for Pfizer’s Liptor and Lilly’s Zyprexa. Lilly can expect a $3bn drop in revenue just from generic forms  of Zyprexa becoming available. Pfizer is thought to have earned around $7.8bn from US sales in the 12 months to September 2011.

By comparison, Oracea is thought to have generated sales of $260m in 2011 for Galderma. So even though Oracea is very expensive compared to 50mg of generic doxycycline, Oracea itself being protected by a long-lasting patent is still small-fry compared to giants like Liptor and Zyprexa.

Metrogel 1% is also protected by patents owned by Galderma, so don’t expect to see similar formulations to Metrogel 1% becoming available before they expire. Galderma will naturally enjoy exclusive marketing and write their own pricing of Sansrosa/CDCD07805/47 should that become available as well.

Patent expiries and emerging pharma markets to fuel $100bn generics growth

Published: 17/01/2012

The global generics market is expected to reach $231bn by 2017, led by patent expiries on blockbuster drugs and the growth of emerging markets, according to a new report.

Analysts at Frost & Sullivan also highlighted impact of government cost-cutting measures and say sales of generics will grow by over $100bn, up from the $123.85bn generated in 2010.

Their Generic Pharmaceuticals Market – A Global Analysis report that generics manufacturers will benefit from the patent expiries of blockbusters, with revenues worth $150bn.

Heading up these are Pfizer’s Lipitor, which lost its patent protection in the US at the end of 2011 and is due to lose exclusivity in Europe in May 2012.

Lilly will also be hit hard by generic competition to its antipsychotic Zyprexa (olanzapine), with revenues of the drug expected to fall by $3bn for 2012.

Related Articles


Read more about: Galderma, patents

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.